Publications by authors named "Anastasia Solomou"
Article Synopsis
- * Among patients treated with colistin, 28.1% developed AKI, with additional factors like voriconazole use contributing to this risk.
- * The study found a 14-day mortality rate of 34.2%, with factors such as bacteraemia from Pseudomonas aeruginosa and the development of AKI significantly impacting survival
Breakthrough bloodstream infections (BSIs) are rare among non-neutropenic patients. Our goal was to determine the risk factors associated with development of breakthrough BSIs among critically ill non-neutropenic patients and its role in mortality. During a 24-month period (August 2016 to July 2018), all BSIs among non-neutropenic patients hospitalized at the University General Hospital of Patras, Greece, were included.
View Article and Find Full Text PDFReversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
J Antimicrob Chemother
July 2019
Objectives: Our aim was to determine the epidemiology of bloodstream infections (BSIs) by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) after the introduction of ceftazidime/avibactam in January 2018 among ICU patients.
Patients And Methods: All patients hospitalized at the ICU of the University General Hospital of Patras, Greece with CP-Kp BSI during 2015-18 were included. MICs of meropenem, fosfomycin, tigecycline and ceftazidime/avibactam (only for isolates from 2018) were determined by Etest, whereas for colistin, the broth microdilution method was applied.